Skip to content

Evaluation and Comparison of Noninvasive Blood Glucose Concentrations

An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01745900
Enrollment
125
Registered
2012-12-10
Start date
2012-12-31
Completion date
2013-03-31
Last updated
2012-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational Diabetes, Insulin Dependent Diabetes, Non Insulin Dependent Diabetes

Keywords

Diabetes, Gestational Diabetes, Female

Brief summary

Comparison of noninvasive glucose measurement performance versus standard invasive reference measurements.

Detailed description

The objectives of this study are * collect subject data on a near-infrared spectroscopy-based glucose meter * evaluate existing instrumentation, calibration algorithms and calibration maintenance techniques * collect data on the physiological and environmental sources of interference and degradation of measurement accuracy.

Interventions

None listed

Sponsors

InLight Solutions
CollaboratorINDUSTRY
VeraLight, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Female aged ≥ 18 and ≤ 50 years of age at time of enrollment * Females with self reported diagnosis of Type I, Type II or Gestational Diabetes, or no self reported diagnosis of diabetes.

Exclusion criteria

* Severe heart disease as evidenced by peripheral edema (self reported) * Currently taking Lasix (self reported) * Liver disease as evidenced by jaundice (self reported) * Receiving dialysis or having known renal compromise (self reported) * Skin damage at optical sampling site * Scars, tattoos, rashes or other disruption/discoloration on the right index finger * Recent (within past month) or current oral steroid therapy or topical steroids applied to the hands; inhaled steroid therapy (self reported) * Current chemotherapy, or chemotherapy within the past 12 months (self reported)

Design outcomes

Primary

MeasureTime frame
Continuing validation of near infrared spectroscopy-based glucose meter algorithm3 months

Countries

United States

Contacts

Primary ContactAmber Brassfield, RN
619-291-2845
Backup ContactAmber Brassfield, RN
619-366-1129

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026